223,077 Shares in Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Acquired by HGC Investment Management Inc.

HGC Investment Management Inc. purchased a new position in Tevogen Bio Holdings Inc. (NASDAQ:TVGN) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 223,077 shares of the company’s stock, valued at approximately $82,000. HGC Investment Management Inc. owned approximately 0.13% of Tevogen Bio at the end of the most recent reporting period.

Insider Buying and Selling

In other news, insider Neal Flomenberg sold 1,078,600 shares of Tevogen Bio stock in a transaction that occurred on Thursday, October 17th. The stock was sold at an average price of $1.62, for a total value of $1,747,332.00. Following the completion of the transaction, the insider now owns 4,254,302 shares in the company, valued at approximately $6,891,969.24. This trade represents a 20.23 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 56.60% of the stock is owned by company insiders.

Tevogen Bio Stock Performance

Tevogen Bio stock opened at $1.18 on Tuesday. The stock’s 50 day simple moving average is $1.32 and its two-hundred day simple moving average is $0.90. Tevogen Bio Holdings Inc. has a 12 month low of $0.26 and a 12 month high of $21.09.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.